Resource Logo
PR Newswire

Parker Hughes Institute Granted Patent for New Anti-AIDS Drug: Temporarily Closes HIV Clinic in Preparation for Stampidine Clinical Trial


ROSEVILLE, Minn. -- On February 26, 2002 the U.S. Patent and Trademark Office granted Parker Hughes Institute a patent (U.S. patent No. 6,350,736) for Stampidine, a new anti-AIDS drug developed at the institute.

Parker Hughes Institute has completed all pre-clinical research and development related to Stampidine and is getting ready to seek FDA approval to initiate clinical trials. Parker Hughes Institute expects to receive that approval and begin clinical trials of Stampidine within the next three to six months.

Minnesota Comprehensive Care Center, the HIV/AIDS clinic operated by the Institute, has been temporarily closed so that the staff may focus on all the necessary preparations needed to initiate the Stampidine clinical trial.

"There's a lot of hard work that needs to be done in order to prepare for this clinical trial and we have made the decision that for now our HIV clinic will focus solely on the Stampidine trial so that we can continue to develop this life saving anti-AIDS drug without delay," said Fatih Uckun, President and Director of Parker Hughes Institute.

SOURCE Parker Hughes Institute

Web Site:


Copyright © 2002 -PR Newswire, Publisher. All rights reserved to PR Newswire.. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PR Newswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019.

Information in this article was accurate in March 28, 2002. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.